K. Luther icaac 2012 finalprogram web4a

151 TUESDAY SCIENTIFIC SESSIONS Final Program D-1458 Chemotherapy-Induced Changes of the Intestinal Micro- biota Analyzed by High Throughput Pyrosequencing

E. Montassier

1 , E. Batard 1 , J. Hardouin 2 , J. Caillon 1 , T. Carton 3 , N. Caroff 1 , T. Gastinne 1 , P. Moreau 1 , G. Potel 1 , M. De la Cochetière 2 , F. Le Vacon 3 ; 1 Ctr. Hosp. Univ. de Nantes, Nantes, France, 2 Faculté de Med. de Nantes, Nantes, France, 3 Biofortis Res., Nantes, France. D-1459 Pyrotyping: A Practical Genotyping Method Compatible to Multilocus Sequence Typing MLST by Pyrosequencing

T. Saga, N. Aoike, Y. Ishii, K. Tateda; Toho Univ., Tokyo, Japan. D-1460

Rapid Identification of Causative Bacteria from Positive Blood Culture Samples by DNA Pyrosequencing

M. Yamada, K. Yanagihara, Y. Morinaga, S. Kohno, S. Kamihira; Nagasaki Univ., Nagasaki, Japan.

D-1461 A Novel TM-Mapping Method that Enables Identification of Pathogenic Microorganisms Within 3 Hours after Samples are Collected

H. Niimi

1 , T. Ueno 1 , S. Hayashi 1 , M. Mori 2 , H. Tabata 3 , H. Minami 3 , S. Saito 1 , I. Kitajima 1 ; 1 Toyama Univ. Hosp., Toyama, Japan, 2 Ishikawa Prefectural Univ., Ishikawa, Japan, 3 Hokkaido Mitsui Chemicals Corp., Hokkaido, Japan. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 173 E Poster Session In Vitro Activity of Lipoglycopeptides and Related Compounds Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-1462 In Vitro Activity of Oritavancin against Gram-Positive Pathogens Isolated in Canadian Hospitals in 2011

J. A. Karlowsky

1,2 , H. Adam 1 , M. Baxter 2 , D. Hoban 1,2 , G. G. Zhanel 2 ; 1 Diagnostic Services of Manitoba, Winnipeg, Canada, 2 Univ. of Manitoba, Winnipeg, Canada. E-1463 A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Oritavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms

N. M. Holliday

1 , D. Zollos 1 , C. C. Knapp 1 , S. B. Killian 1 , F. F. Arhin 2 , G. Moeck 2 , J. M. Streit 3 , R. N. Jones 3 , R. R. Prochaska 3 , P. R. Rhomberg 3 , L. Sykes 4 ; 1 TREK Diagnostic Systems, Cleveland, OH, 2 The Med. Com- pany, Parsippany, NJ, 3 JMI Lab., North Liberty, IA, 4 Kaiser Permanente, Cleveland, OH. E-1464 Evaluating the Activity of Daptomycin DAP and Linezolid LND in Combination with Rifampin RIF or Gentamicin GENT on Enterococcus faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations SEV

M. K. Luther

1 , K. M. Babcock 1 , K. L. LaPlante 1,2 , A. R. Caffrey 1,3 ; 1 Provi- dence VA ID Res. Program, Providence, RI, 2 Univ. of Rhode Island, Kings- ton, RI, 3 Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI. E-1465 In Vitro Development of Daptomycin Resistance DAP-R After Exposure to DAP of Enterococcus faecalis EF Bloodstream Isolates from Patients with Infective Endocarditis IE C. Garcia-de-la-Maria, J. M. Pericas, A. del-Rio, Y. Armero, Biologist, X. Castañeda, C. Cervera, M. Almela, C. Falces, S. Ninot, C. A. Mestres, D. Soy, J. M. Gatell, A. Moreno, F. Marco, J. M. Miro, Hospital Clinic Endo- carditis Study Group; Hosp. Clinic - IDIBAPS, Barcelona, Spain. E-1466 Efficacy of Daptomycin DAP and Ceftaroline CPT in Methicillin- Resistant Staphylococcus aureus MRSA Candida glabrata CG Polymicrobial Biofilms

J. M. Rybak

1,2 , J. A. Vazquez 2 ; 1 Eugene Applebaum Coll. of Pharm. and Hlth. Sci., Detroit, MI, 2 Henry Ford Hosp., Detroit, MI. E-1467 A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms

S. B. Killian

1 , N. M. Holliday 1 , C. C. Knapp 1 , D. Zollos 1 , M. Dunne 2 , J. M. Streit 3 , R. N. Jones 3 , R. R. Prochaska 3 , P. R. Rhomberg 3 , L. Sykes 4 ; 1 TREK Diagnostic Systems, Cleveland, OH, 2 Durata Therapeutics, Inc., Morristown, NJ, 3 JMI Lab., North Liberty, IA, 4 Kaiser Permanente, Cleve- land, OH. E-1468 Telavancin in the Therapy of Experimental Aortic Valve Endocarditis in Rabbits Due to Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus MRSA Y. Q. Xiong 1,2 , W. A. Hady 1 , A. S. Bayer 1,2 , L. Chen 3 , S. Yang 1,2 ; 1 Harbor- UCLA, Torrance, CA, 2 David Geffen Sch. of Med. UCLA, Los Angeles, CA, 3 Publ. Hlth. Res. Inst. Tuberculosis Ctr., Newark, NJ. E-1469 Activity Of Telavancin TLV, Daptomycin DAP, Linezolid LND, and Vancomycin VAN against Clinical Heterogeneous Vancomycin-Intermediate Staphylococcus aureus hVISA in a Simulated In Vitro Pharmacodynamic IVPD Infection Model

M. K. Luther

1 , K. M. Babcock 1 , A. R. Caffrey 1,2 , K. L. LaPlante 1,2 ; 1 Provi- dence VA ID Res. Program, Providence, RI, 2 Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI. E-1470 In Vitro Activity of Telavancin and Other Non-ß-Lactam An- tibiotics in Methicillin Resistant Staphylococcus aureus Hospital- Acquired MRSA versus Community-Acquired MRSA in Austria E. Leitner, G. Zarfel, G. Feierl, U. Wagner-Eibel, M. Gehrer, E. Marth, A. Grisold; Inst. of Hygiene, Microbio. and Environmental Med., Graz, Austria. ------------------------------------------------------------------------ 174 E Poster Session In Vitro Activity Versus Staphylococcal Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-1471 In Vitro Activity of Vancomycin, Linezolid and Tigecycline against Methicillin-Resistant Staphylococcus aureus MRSA Bloodstream Isolates and Outcomes in Patients with MRSA Bacteremia of the Medical Hospital of Vienna From 2000-2011 C. Forstner, C. Dungl, S. Tobudic, H. Burgmann; Med. Univ. of Vienna, Vienna, Austria.